Wednesday, 21 April 2021
No Result
View All Result
eudebates.tv
  • EU Policies
  • World
  • Special Debates
  • Events
  • Vote & Polls
eudebates.tv
No Result
View All Result
Home Debates EU Policies Health

EMA transparency and independence standards for treatments and vaccines

EUdebates Team by EUdebates Team
13/02/2021
in Health
Reading Time: 5 mins read
0
Exterior of European Medicines Agency in Amsterdam - EMA
14
SHARES
139
VIEWS
Share on FacebookShare on Twitter

Join EU debates

Health: Keep mothers and newborns together

World Health Day: Stella Kyriakides EU debates Health Union

India donates 200,000 vaccine doses to UN blue helmets peacekeepers

President von der Leyen looks to speed up vaccine rollout

The European Medicines Agency (EMA) has re-affirmed its long-standing commitment to independence and transparency in its evaluation of COVID-19 treatments and vaccines. Tried and tested measures ensure that EMA’s recommendations are driven only by science and public-health needs, and not by any other interests.

The scale of the COVID-19 public health crisis has led to unprecedented efforts by all those involved in the development of medicines to treat and prevent COVID-19, compressing a process that typically requires several years into one lasting only several months.

EMA and the national competent authorities have responded to these challenges by fully mobilising their resources to expedite their advice and evaluation processes, while maintaining their safety and efficacy standards and applying tested independence and EMA transparency rules. MEPs called for complete transparency regarding contracts and deployment of COVID-19 vaccines.

EMA transparency and OLAF controls

Maximum EMA transparency a pre-condition

EMA considers maximum transparency as a pre-condition for fostering trust and confidence in the EU regulatory system. It is also planning a range of additional measures to provide the public prompt insights into its development and safety-monitoring processes. This includes for example the publication of the product information with details of the conditions of use even before the formal marketing authorisation will be granted. Then follows the expedited publication of the full European Public Assessment Report (EPAR) and the publication of the risk management plans for authorised COVID-19 medicines in their entirety, rather than as a summary.

EU leaders see ‘dark red’ and urge Brussels and EMA to speed up vaccine delivery

In an PDF iconopen letter sent to European Ombudsman Emily O’Reilly in response to an enquiry on the role of EMA and its pandemic task force during the COVID-19 crisis, the Agency explains that it is applying the same independence measures to its experts dealing with COVID-19 treatments and vaccines as it does for those dealing with all medicines. This includes the experts involved in providing advice on these medicines’ development, as well as the experts evaluating them.

The letter also sets out the EMA transparency plans for COVID-19 treatments and vaccines. EMA will publish the clinical data underpinning its recommendations for all COVID-19 medicines. This falls under the scope of EMA’s landmark policy on proactive publication of clinical data, which the Agency is reinstating – exclusively for COVID-19 medicines at this point – following its suspension in August 2018 to allow the Agency to focus resources on its relocation from the United Kingdom to the Netherlands.

MEPs call for more clarity and transparency

Members of the European Parliament debate on the latest developments regarding contracts, transparency, authorisations, availability and deployment of COVID-19 vaccines. MEPs underlined the need for more clarity and transparency regarding vaccine contracts, as well as the decision-making process at EU level. They welcomed the European Commission’s openness to share available information whilst also acknowledging that some questions can be better answered by member states and pharmaceutical companies.

Many debate parliamentary questions concern possible additional national or bilateral contracts. The Commission confirms that it is not aware of any such alleged contracts. Through the Joint Procurement Agreement, the EU has priority to deliver vaccines, which will then be distributed to member states on a pro-rata basis.

Ursula von der Leyen admits to failings in vaccine EU plan

Many members emphasize that the EU had made the right key decisions, especially on the collective European approach to vaccination and on standing up for its citizens’ rights by putting safety first and enforcing EU liability rules.

In order to build citizens’ trust in the vaccination efforts and avoid disinformation, the EU must “tell the truth”, some MEPs pointed out. In this respect, many recalled the need for transparency with regard to contracts, as well as for comprehensive and clear data on vaccines rollout at national level.

“And yet it is a fact that we are not today where we want to be in the fight against the virus,” Ursula von der Leyen told EU lawmakers.

“We were late with the approval. We were too optimistic on mass production. And perhaps we were also too certain that the orders would actually be delivered on time,” she said.

Following requests from MEPs, the Commission provided information regarding a number of other specific issues:

  • A reading room is open for MEPs wishing to review vaccine contracts and agreements with pharmaceutical companies;
  • The largest quantities of vaccines will be during the second quarter of 2021, as already agreed in the existing contracts – specific strategies for deployment, including priority groups for vaccination, are set up by each member state;
  • A dedicated platform will be available where member states can report, twice a week, the number of vaccines received and used.

The European Medicines Agency (EMA) plays an important role in enabling the development, scientific evaluation, approval and monitoring of COVID-19 vaccines in the European Union (EU). Vaccines for COVID-19 are being developed, evaluated and approved according to current regulatory guidelines and legal requirements.

eudebates EMA transparency and independence

Share this debate with your friends!
Follow #eudebates on Google News and on Facebook
Tags: CoronavirusCOVIDCOVID19EU MEMBEREuropean Medicines Agency (EMA)European ParliamentMembers of the European ParliamentMEPTransparencyUrsula von der LeyenVaccinationVaccinationsVaccines
Share6Tweet4

Get real time update about this post categories directly on your device, subscribe now.

Unsubscribe

Related EU debates

small-baby mother newborn
Health

Health: Keep mothers and newborns together

16/04/2021
Stella Kyriakides, European Commissioner for Health and Food Safety
Health

World Health Day: Stella Kyriakides EU debates Health Union

06/04/2021
India donates 200,000 vaccines to protect UN blue helmets against COVID
Health

India donates 200,000 vaccine doses to UN blue helmets peacekeepers

29/03/2021
Ursula von der Leyen President of the European Commission
Health

President von der Leyen looks to speed up vaccine rollout

17/03/2021
The label of the empty vial is crossed out to prevent further fraud and thrown into a specific container
Health

WHO: Do not STOP vaccinations of AstraZeneca Vaccine

16/03/2021
Astrazeneca Doses of the COVID-19 vaccine in a fridge
Health

EMA investigates AstraZeneca Vaccine and thromboembolic events

16/03/2021

Leave a Reply Cancel reply

Your email address will not be published.

Maroš Šefčovič, Vice-President of the European Commission in charge of Interinstitutional relations and Foresight

Šefčovič hold ‘productive’ talks with Lord Frost on Northern Ireland crisis

19/04/2021
Mr Charles MICHEL, President of the European Council; Mr Volodymyr ZELENSKYY, President of Ukraine

President Michel promises support to Ukraine President Zelenskyy

16/04/2021
small-baby mother newborn

Health: Keep mothers and newborns together

16/04/2021
Halloumi cheese from Cyprus

Halloumi Cyprus cheese joins EU PDO – Protected designation of origin

12/04/2021
Europol building

EU serious and organised crime threat assessment (SOCTA) 2021

12/04/2021
eye-controls AI Artificial Intelligence Technology

AI technologies must prevent discrimination and protect diversity

11/04/2021
  • Nigel Farage

    EU nasty and vindictive? Nigel Farage criticizes EU vaccines strategy

    78 shares
    Share 31 Tweet 20
  • EU: AstraZeneca logic can only work at the neighbourhood butchers

    54 shares
    Share 22 Tweet 14
  • EU Health Emergency Preparedness and Response Authority (HERA)

    49 shares
    Share 20 Tweet 12
  • Why don’t we print money for Corona Crisis?

    113 shares
    Share 114 Tweet 72
  • After Brexit will the UK lose the Falkland Islands?

    42 shares
    Share 17 Tweet 11

Join eudebates newsletter!

Enter your email to receive our newsletter.

Don't worry, we don't spam
eudebates.tv

Welcome to eudebates.tv the unique european initiative to promote debate, dialogue and communication among citizens for a better Europe.

Follow us on social media:

Recent News

  • Šefčovič hold ‘productive’ talks with Lord Frost on Northern Ireland crisis
  • President Michel promises support to Ukraine President Zelenskyy
  • Health: Keep mothers and newborns together
  • Halloumi Cyprus cheese joins EU PDO – Protected designation of origin
  • EU serious and organised crime threat assessment (SOCTA) 2021

Newsletter

Join eudebates newsletter!

Enter your email to receive our newsletter.

Don't worry, we don't spam
Maroš Šefčovič, Vice-President of the European Commission in charge of Interinstitutional relations and Foresight

Šefčovič hold ‘productive’ talks with Lord Frost on Northern Ireland crisis

19/04/2021
Mr Charles MICHEL, President of the European Council; Mr Volodymyr ZELENSKYY, President of Ukraine

President Michel promises support to Ukraine President Zelenskyy

16/04/2021
small-baby mother newborn

Health: Keep mothers and newborns together

16/04/2021
  • Home
  • EU Policies
  • Special Debates
  • Events
  • Vote & Polls
  • Video

© 2021 eudebates - EU debates, dialogue, communication for a better Europe - Privacy Policy.

No Result
View All Result
  • EU Policies
  • World
  • Special Debates
  • Events
  • Vote & Polls

© 2021 eudebates - EU debates, dialogue, communication for a better Europe - Privacy Policy.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In